Chemical myectomy with mavacamten in patients with obstructive hypertrophic cardiomyopathy with prior septal reduction therapy: A single-center experience

Hypertrophic cardiomyopathy (HCM) is a heterogenous genetic cardiac condition affecting 1 in 200 to 500 people. About 70% of these patients will have clinical symptoms from left ventricular outflow tract (LVOT) obstruction, defined as an LVOT gradient (LVOTG) ≥30 mm Hg at rest or after provocation.1 The first-line treatment comprises beta-blockers, calcium channel blockers, and disopyramide; however, these do not address the molecular pathophysiology of HCM. When medical treatment fails, invasive septal reduction therapy (SRT) is considered, although residual obstruction can occur.